In vitro, ruxolitinib treatment blocked STAT phosphorylation and strongly decreased both proliferation of NK cells and the killing capability of NK cells against carcinoma cells, indicating that JAK/STAT pathway inhibition impairs the anti-tumor potential of NK cells. The gene discussed is SOAT1; the disease is neoplasm.